Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis

Abstract

Background: Methylthioadenosine (MTA) is a natural metabolite with immunomodulatory properties. MTA improves the clinical course and pathology of the animal model of multiple sclerosis, even when therapy is started after disease onset. Objective: Our aim was to compare the efficacy of MTA in ameliorating experimental autoimmune encephalomyelitis (EAE) compared with first line approved therapies, to develop an oral formulation of MTA and to assess its pharmacokinetic profile.

Methods: EAE was induced in C57BL/6 mice by immunization with MOG_35-55 peptide in Freund’s Adjuvant. Animals were treated with MTA, interferon-beta or Glatiramer acetate starting the day of immunization and the clinical score was collected blind. Pharmacokinetic studies were performed in Sprague Dawley rats by administering MTA by intraperitoneal injection and orally, and collecting blood at different intervals. MTA levels were measured by high-performance liquid chromatography.

Results: We found that MTA ameliorated EAE in a dose—response manner. Moreover, the highest dose of MTA (60 mg/kg) was more efficacious than mouse interferon-beta or Glatiramer acetate. We developed a salt of MTA for oral administration, with similar dose—response effect in the EAE model. Combination therapy assays between MTA and interferon-beta or Glatiramer acetate were more effective than the individual therapies. Finally, oral MTA half-life was 20 min, with a C_max of 80 mg/L and without signs of obvious toxicity (animal death, behavioural changes, liver enzymes). Conclusions: In the EAE model MTA is more efficacious than first line therapies for multiple sclerosis, with a dose— response effect and higher efficacy when combined with interferon-beta or Glatiramer acetate. Oral MTA was also effective in the animal model of multiple sclerosis.

Keywords

methylthioadenosine multiple sclerosis preclinical development oral pharmacokinetics

Get full access to this article

View all access options for this article.

References

Avila MA , Garcia-Trevijano ER , Lu SC , et al. Methylthioadenosine. Int J Biochem Cell Biol 2004; 36: 2125-2130.

Moreno B. , Hevia H. , Santamaria M. , et al. Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 2006; 60: 323-334.

Lawson BR , Manenkova Y. , Ahamed J. , et al. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J Immunol 2007; 178: 5366-5374.

Hauser SL and Oksenberg JR The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration . Neuron 2006; 52: 61-76.

Bhat R. and Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009; 64: 123-132.

Palacios R. , Goni J. , Martinez-Forero I. , et al. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE 2007; 2: e1222.

Wang Y. , Feng D. , Liu G. , et al. Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J Immunol 2008; 181: 8226-8236.

Stüve O. , Yousself S. , Weber MS , et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116(4): 1037-1044.

Giuliani F. , Fu SA , Metz LM and Yong VW Effective combination of minocicline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 2005; 165: 83-91.

10.

Compston A. and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.

11.

Hemmer B. and Hartung HP

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

Ann Neurol 2007; 62: 314-326.

12.

Villoslada P. , Moreno B. , Melero I. , et al. Immunotherapy for neurological diseases . Clin Immunol 2008; 128: 294-305.

13.

Stramentinoli G. and Gennari F. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle. US 1984; 4,454,122: 20-33.

14.

Moratti E. Pharmaceutical compositions containing 5′-deoxy-5′-methylthioadenosine s-adenosylmethionine and their salts for reducing seborrhea. US 1998; 5,753,213: 12-22.